Cytokine News and Research

RSS

New tools for detecting and monitoring TB in captive elephants

Mycobacterium tuberculosis, the organism that causes tuberculosis in humans, also afflicts Asian (and occasionally other) elephants. Diagnosing and treating elephants with TB is a challenge, however, as little is known about how their immune systems respond to the infection.

16 Jul 2014

Immune marker predicts infection risk in critically ill children with traumatic injuries

Researchers studying critically ill children with traumatic injuries have identified an immune marker that predicts which patients are likely to develop a hospital-acquired infection.

10 Jul 2014

Loss of p62 protein in cells and tissue surrounding a tumor can influence tumor growth

A team of scientists from Sanford Burnham Medical Research Institute has found that the loss of a protein called p62 in the cells and tissue surrounding a tumor can enhance the growth and progression of tumors.

4 Jul 2014

New article explores how specific types of interferons control RNA virus infection

Respiratory and intestinal infections caused by RNA viruses stimulate infected cells to produce interferons, which can act alone or in combination to block virus replication.

27 Jun 2014

Alcoholic liver disease: an interview with Dr Vinood Patel, University of Westminster

Alcoholic liver disease (ALD) is one of the leading causes of death worldwide and also in the UK. As its name indicates this disease arises due to consuming excessive amounts of alcohol (80 g/day) over an extended period, normally 10-20 years.

24 Jun 2014

Type I interferons can block development of allergy- and asthma-driving Th2 cells

A mechanism that could underlie the development of cells that drive asthma and allergies has been uncovered by immunology researchers at UT-Southwestern Medical Center.

17 Jun 2014

Scientists identify novel approach to treating multiple sclerosis

Scientists in the University of Connecticut's Technology Incubation Program have identified a novel approach to treating multiple sclerosis (MS) using human embryonic stem cells, offering a promising new therapy for more than 2.3 million people suffering from the debilitating disease.

17 Jun 2014

Mechanisms of recurrent bacteria AOM in children under scrutiny

The immune response in young children with bacterial acute otitis media differs between individuals who are prone to such infection and those who are not, US researchers have shown.

16 Jun 2014

ImStem successfully treats animal model of multiple sclerosis using hESC

ImStem Biotechnology, Inc. (ImStem) announced today it has successfully treated an animal model of multiple sclerosis (MS) using human embryonic stem cells (hESC) derived mesenchymal stem cells (MSCs), called hES-MSCs.

6 Jun 2014

Shire intends to submit NDA for lifitegrast to treat dry eye disease

Following a May 15, 2014, meeting with the U.S. Food and Drug Administration (FDA), Shire plc, the global specialty biopharmaceutical company, announces today that it intends to submit a New Drug Application for lifitegrast as a treatment for the signs and symptoms of dry eye disease in adults in the first-quarter 2015, as we complete remaining chemistry and manufacturing work.

19 May 2014

Eleven Biotherapeutics reports financial results and operational highlights for Q1 2014

Eleven Biotherapeutics, Inc., a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results and operational highlights for the quarter ended March 31, 2014.

15 May 2014

MedImmune to present Phase IIb asthma data on benralizumab and tralokinumab at ATS conference

AstraZeneca today announced that MedImmune, its global biologics research and development arm, will present Phase IIb data on two novel investigational molecules – benralizumab and tralokinumab – at the upcoming American Thoracic Society 2014 International Conference being held in San Diego, California, 16-21 May.

14 May 2014

Baylor receives patent for islet cell transplantation in patients with type1 diabetes, chronic pancreatitis

Baylor Research Institute has been awarded a patent from the U.S. Patent Office for a potential strategy to improve the outcomes of islet cell transplantation for patients with type 1 diabetes and chronic pancreatitis.

14 May 2014

Inovio Pharmaceuticals reports total revenue of $2.4 million for first quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2014.

12 May 2014

New study explores how bacterial pathogen Yersinia tries to outsmart immune cell responses

A new study led by scientists at the University of Pennsylvania School of Veterinary Medicine has painted a clearer picture of the delicate arms race between the human immune system and a pathogen that seeks to infect and kill human cells.

6 May 2014

Debiopharm signs new license and research agreement with Yale University

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, announced it has signed a new license and research agreement with Yale University (Yale), a premier university with a long tradition of basic and clinical biomedical research, regarding the discovery of MIF inhibitors for treatment of autoimmune and inflammatory diseases.

6 May 2014

Study shows pro-inflammatory cytokine TNF-α can speed recovery in mouse with pulmonary fibrosis

Inflammation has long been considered an integral part of the biological process that leads to deadly scarring in idiopathic pulmonary fibrosis. New research at National Jewish Health, however, suggests that a little inflammation may also be crucial to the healing and repair processes in the lungs.

26 Apr 2014

Studies identify 2 genes highly associated with IBD

Inflammatory Bowel Disease (IBD), a group of chronic inflammatory disorders of the intestine that result in painful and debilitating complications, affects over 1.4 million people in the U.S., and while there are treatments to reduce inflammation for patients, there is no cure.

23 Apr 2014

XBiotech announces results from Phase I/II oncology study

XBiotech is announcing that results from its Phase I/II oncology study conducted at MD Anderson Cancer Center in Houston, TX were published today in Lancet Oncology. The featured article describes the outcome in 52 advanced cancer patients treated with Xilonix™, XBiotech's novel, non-cytotoxic, anti-tumor therapy.

18 Apr 2014

New drug combination proves effective in treating patients with HCV genotype 1

Treatment options for the 170 million people worldwide with chronic Hepatitis C Virus (HCV) are evolving rapidly, although the available regimens often come with significant side effects. Two multi-center clinical trials led by Beth Israel Deaconess Medical Center show promise for a new option that could help lead to both an increase in patients cured with a much more simple and tolerable all oral therapy.

15 Apr 2014